Anke Biotech (300009.SZ): AFN0328 injection was accepted for drug registration

Anke Biotech (300009.SZ) announced that the clinical trial application for the “AFN0328 injection” jointly declared by the company and participating companies Hefei Afana Biotechnology Co., Ltd. (“Afana Company”) and Hefei Afana Anke Biotechnology Co., Ltd. has been accepted, and the administrative licensing document “Notice of Acceptance” has been obtained from the State Drug Administration.

Zhitong FinanceApr 29 18:26

Express News | Anke Biotech: New Indications for Injectable Human Growth Hormone Obtain Drug Clinical Trial Approval Notice

BreakingsApr 29 17:05

Cinda Securities released a research report on April 26 stating that it gave Anke Biotech (300009.SZ) a purchase rating. The main reasons for the rating include: 1) excellent performance in 2023, steady revenue growth in 24Q1; 2) the main business, biolog

Cinda Securities released a research report on April 26 stating that it gave Anke Biotech (300009.SZ) a purchase rating. The main reasons for the rating include: 1) excellent performance in 2023, steady revenue growth in 24Q1; 2) the main business, biological products, maintained a continuous growth trend. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 26 15:17

Anke Biotech (300009): Steady revenue growth promotes continuous empowerment of new drug development

Incident: Anke Biotech released its 2024 quarterly report. 2024Q1 achieved revenue of 656 million yuan, an increase of 10.42% over the previous year, and achieved net profit of 218 million yuan to mother, an increase of 17.31% over the previous year. Reviews:

信達證券Apr 26 00:00

Anke Biotech (300009.SZ) announced first-quarter results, net profit of 218 million yuan, an increase of 17.31%

According to the Zhitong Finance App, Anke Biotech (300009.SZ) released its report for the first quarter of 2024. The company's revenue was 656 million yuan, an increase of 10.42% over the previous year. Net profit attributable to shareholders of listed companies was 218 million yuan, an increase of 17.31% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 205 million yuan, an increase of 15.03% over the previous year. Basic earnings per share were $0.1299.

Zhitong FinanceApr 25 18:26

Pharmaceutical stocks fluctuated and declined. Zhifei Biotech, Baiyang Pharmaceutical, Tuoxin Pharmaceutical, and Baicheng Pharmaceutical all fell by more than 10%, while Anke Biotech and Tebao Biotech fell more than 8%.

Pharmaceutical stocks fluctuated and declined. Zhifei Biotech, Baiyang Pharmaceutical, Tuoxin Pharmaceutical, and Baicheng Pharmaceutical all fell by more than 10%, while Anke Biotech and Tebao Biotech fell more than 8%.

Zhitong FinanceApr 23 10:43